Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Accumulated Depreciation (2025)

Benitec Biopharma has reported Accumulated Depreciation over the past 1 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation at $1.5 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $1.5 million (changed N/A YoY), and the annual figure for FY2025 was $1.5 million, changed.
  • Accumulated Depreciation reached $1.5 million in Q4 2025 per BNTC's latest filing, up from $1.5 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $1.5 million in Q4 2025 and bottomed at $1.5 million in Q2 2025.